Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969410 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL12435659 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL9969411 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL14357378 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL12939631 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL14357099 | 1.00 | SLC6A4 (0.57) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL22810963 | 0.83 | SLC6A4 (0.53) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL1961679 | 0.80 | KDM4E (0.65) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL765762 | 0.80 | KDM4E (0.65) | SLC6A4KDM4EADRA2CLMNAADRA2A | |
| SCHEMBL28263575 | 0.80 | KDM4E (0.65) | SLC6A4KDM4EADRA2CLMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10316080-B2 | Protein-polymer-drug conjugates | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150366982-A1 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | MERSANA THERAPEUTICS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SLC6A4 4466/4885KDM4E 1873/4885ADRA2C 4451/4885 |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SLC6A4 4550/4885KDM4E 2904/4885ADRA2C 4264/4885 |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SLC6A4 4466/4885KDM4E 1873/4885ADRA2C 4451/4885 |
| US-10316080-B2 | Protein-polymer-drug conjugates | PBRM1, STAMBP, TSPO | SLC6A4 4466/4885KDM4E 1873/4885ADRA2C 4451/4885 |
| US-20150366982-A1 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | PBRM1, BCR, ERBB2 | SLC6A4 4412/4885KDM4E 2425/4885ADRA2C 4398/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | SLC6A4 4550/4885KDM4E 2904/4885ADRA2C 4264/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SLC6A4 4466/4885KDM4E 1873/4885ADRA2C 4451/4885 |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | SLC6A4 4277/4885KDM4E 1049/4885ADRA2C 4187/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | SLC6A4 4397/4885KDM4E 2017/4885ADRA2C 2779/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | SLC6A4 4550/4885KDM4E 2904/4885ADRA2C 4264/4885 |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | PBRM1, HDGFL3, CLTB | SLC6A4 4585/4885KDM4E 1973/4885ADRA2C 4213/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | SLC6A4 2959/4885KDM4E 2843/4885ADRA2C 4274/4885 |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SLC6A4 4466/4885KDM4E 1873/4885ADRA2C 4451/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | SLC6A4 4454/4885KDM4E 2315/4885ADRA2C 4245/4885 |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | CD2BP2, DNPEP, LNPEP | SLC6A4 2959/4885KDM4E 2843/4885ADRA2C 4274/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | SLC6A4 3603/4885KDM4E 3327/4885ADRA2C 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.